Myeloproliferative neoplasm laboratory findings: Difference between revisions
Line 16: | Line 16: | ||
| doi = 10.1309/AJCPUN89CXERVOVH | | doi = 10.1309/AJCPUN89CXERVOVH | ||
| pmid = 19605820 | | pmid = 19605820 | ||
}}</ref><ref name="Sánchez-MuñozAlvarez-Twose2011">{{cite journal|last1=Sánchez-Muñoz|first1=Laura|last2=Alvarez-Twose|first2=Ivan|last3=García-Montero|first3=Andrés C|last4=Teodosio|first4=Cristina|last5=Jara-Acevedo|first5=María|last6=Pedreira|first6=Carlos E|last7=Matito|first7=Almudena|last8=Morgado|first8=Jose Mario T|last9=Sánchez|first9=Maria Luz|last10=Mollejo|first10=Manuela|last11=Gonzalez-de-Olano|first11=David|last12=Orfao|first12=Alberto|last13=Escribano|first13=Luis|title=Evaluation of the WHO criteria for the classification of patients with mastocytosis|journal=Modern Pathology|volume=24|issue=9|year=2011|pages=1157–1168|issn=0893-3952|doi=10.1038/modpathol.2011.84}}</ref> | }}</ref><ref name="Sánchez-MuñozAlvarez-Twose2011">{{cite journal|last1=Sánchez-Muñoz|first1=Laura|last2=Alvarez-Twose|first2=Ivan|last3=García-Montero|first3=Andrés C|last4=Teodosio|first4=Cristina|last5=Jara-Acevedo|first5=María|last6=Pedreira|first6=Carlos E|last7=Matito|first7=Almudena|last8=Morgado|first8=Jose Mario T|last9=Sánchez|first9=Maria Luz|last10=Mollejo|first10=Manuela|last11=Gonzalez-de-Olano|first11=David|last12=Orfao|first12=Alberto|last13=Escribano|first13=Luis|title=Evaluation of the WHO criteria for the classification of patients with mastocytosis|journal=Modern Pathology|volume=24|issue=9|year=2011|pages=1157–1168|issn=0893-3952|doi=10.1038/modpathol.2011.84}}</ref><ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates|title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= |pages= |isbn=0-443-06377-X |pages=586}}</ref> | ||
*[[Complete blood count]] | *[[Complete blood count]] | ||
:*Increased [[granulocyte]]s of all types | :*Increased [[granulocyte]]s of all types | ||
Line 22: | Line 22: | ||
:*[[Thrombocytopenia]] | :*[[Thrombocytopenia]] | ||
:*[[Anemia]] | :*[[Anemia]] | ||
:*Red blood cell mass test | |||
*Blood chemistry | *Blood chemistry | ||
:*The following blood levels may be elevated: | :*The following blood levels may be elevated: | ||
Line 48: | Line 49: | ||
*Polymerase chain reaction | *Polymerase chain reaction | ||
:*Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample. | :*Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample. | ||
* Neutrophil alkaline phosphatase level | * Neutrophil alkaline phosphatase level | ||
* Vitamin B12 (or B12 binding capacity) | * Vitamin B12 (or B12 binding capacity) | ||
* Serum urate | |||
* Serum urate | |||
==References== | ==References== |
Revision as of 14:18, 26 October 2015
Myeloproliferative Neoplasm Microchapters |
Differentiating myeloproliferative neoplasm from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Myeloproliferative neoplasm laboratory findings On the Web |
American Roentgen Ray Society Images of Myeloproliferative neoplasm laboratory findings |
Directions to Hospitals Treating Myeloproliferative neoplasm |
Risk calculators and risk factors for Myeloproliferative neoplasm laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Laboratory findings consistent with the diagnosis of myeloproliferative neoplasm include leukocytosis, thrombocytopenia, and anemia.
Laboratory Findings
Laboratory findings associated with chronic myelogenous leukemia include:[1][2][3][4]
- Increased granulocytes of all types
- Increased basophils and eosinophils
- Thrombocytopenia
- Anemia
- Red blood cell mass test
- Blood chemistry
- The following blood levels may be elevated:
- Blood urea nitrogen (BUN)
- Creatinine
- Phosphate
- Lactate dehydrogenase (LDH)
- Alanine aminotransferase (ALT)
- Aspartate transaminase (AST)
- Uric acid
- Bleeding and clotting factor
- The following blood levels may be elevated:
- Prothrombin time (PT) or international normalized ratio (INR)
- Partial thromboplastin time (PTT)
- Cytochemistry helps determine the type of cells that are present
- Flow cytometry helps determine the type of cells that are present
- Chromosome changes that may occur in some people with leukemia include:
- Translocations
- Inversions
- loss or gain of a chromosome number
- Similar to cytogenetics, but more specific
- Polymerase chain reaction
- Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
- Neutrophil alkaline phosphatase level
- Vitamin B12 (or B12 binding capacity)
- Serum urate
References
- ↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
- ↑ James W. Vardiman (2009). "Chronic myelogenous leukemia, BCR-ABL1+". American journal of clinical pathology. 132 (2): 250–260. doi:10.1309/AJCPUN89CXERVOVH. PMID 19605820. Unknown parameter
|month=
ignored (help) - ↑ Sánchez-Muñoz, Laura; Alvarez-Twose, Ivan; García-Montero, Andrés C; Teodosio, Cristina; Jara-Acevedo, María; Pedreira, Carlos E; Matito, Almudena; Morgado, Jose Mario T; Sánchez, Maria Luz; Mollejo, Manuela; Gonzalez-de-Olano, David; Orfao, Alberto; Escribano, Luis (2011). "Evaluation of the WHO criteria for the classification of patients with mastocytosis". Modern Pathology. 24 (9): 1157–1168. doi:10.1038/modpathol.2011.84. ISSN 0893-3952.
- ↑ Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.